Shares of Future FinTech Group (FTFT) dropped 28.61% after reversing previous gains, following a recent reverse stock split. Swarmer (SWMR) declined 28.36% as its post-IPO lock-up period expired, increasing potential share supply. Enova International (ENVA) fell 23.43% after withdrawing regulatory applications and canceling its planned acquisition of Grasshopper Bancorp, citing unclear regulatory standards and political pressures. Leveraged ETFs like 2x XRP ETF (XRPT) and ProShares Ultra CRCL (CRCA) also saw steep losses due to declines in their underlying assets. These moves reflect a mix of corporate developments and market volatility impacting stock prices and leveraged products.
The top stock market losers today include Future FinTech Group (FTFT), Swarmer (SWMR), and Enova International (ENVA). For readers following the Financials sector, here is Pluang's market snapshot as of Sep 16, 2026 04:03 WIB: out of 74 priced Financials-sector US stocks tradable on Pluang, 28 rose and 45 fell. Among these, Affirm Holdings Inc (AFRM) declined by 1.88% to USD 72.00, Deutsche Bank AG (DB) dropped 1.78% to USD 39.76, while Allstate Corp (ALL) increased by 1.74% to USD 258.13.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
